300147，被ST

Core Viewpoint - Xiangxue Pharmaceutical has been penalized for information disclosure violations, leading to a warning and fines for its actual controller, Wang Yonghui, and other executives, while the company's stock has been marked with risk warnings due to false financial reporting [2][6]. Summary by Sections Company Penalties and Stock Status - On March 23, Xiangxue Pharmaceutical announced that Wang Yonghui received a warning and a fine of 10 million yuan, with several others also penalized. The company's stock will be marked with risk warnings, changing its name to "ST Xiangxue" while retaining the stock code "300147" [2]. - The stock will be suspended for one day starting March 24, 2025, and will resume trading on March 25, 2025 [2]. Violations and Financial Misreporting - The company was found to have false records in its 2019 annual report, which inflated profits by 53.83 million yuan, accounting for 45.98% of the total reported profit for that year [3]. - From 2016 to 2020, Xiangxue Pharmaceutical failed to disclose significant non-operating fund occupations involving related parties, with amounts of 585 million yuan, 845 million yuan, 1.408 billion yuan, 657 million yuan, and 1.357 billion yuan respectively [4]. Related Party Transactions - The company engaged in transactions that resulted in non-operating fund occupations, with undisclosed amounts in annual reports from 2016 to 2019, only revealing 1.262 billion yuan in the 2020 report [4][5]. - The undisclosed fund occupations represented significant percentages of the company's net assets, ranging from 2.22% to 38.79% across the years [4][5]. Management Accountability - Wang Yonghui was identified as the organizer of the fund occupation activities, leading to penalties for him and other executives, with fines ranging from 150,000 to 2 million yuan [6].